Suppr超能文献

质子泵抑制剂口服固体制剂的延迟释放薄膜包衣应用:案例研究。

Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.

机构信息

Colorcon, Inc., West Point, PA 19486, USA.

出版信息

Drug Dev Ind Pharm. 2010 Feb;36(2):180-9. doi: 10.3109/03639040903468811.

Abstract

BACKGROUND

Formulation of proton pump inhibitors (PPIs) into oral solid dosage forms is challenging because the drug molecules are acid-labile. The aim of this study is to evaluate different formulation strategies (monolithic and multiparticulates) for three PPI drugs, that is, rabeprazole sodium, lansoprazole, and esomeprazole magnesium, using delayed release film coating applications.

METHOD

The core tablets of rabeprazole sodium were prepared using organic wet granulation method. Multiparticulates of lansoprazole and esomeprazole magnesium were prepared through drug layering of sugar spheres, using powder layering and suspension layering methods, respectively. Tablets and drug-layered multiparticulates were seal-coated, followed by delayed release film coating application, using Acryl-EZE(R), aqueous acrylic enteric system. Multiparticulates were then filled into capsules. The final dosage forms were evaluated for physical properties, as well as in vitro dissolution testing in both compendial acid phase, 0.1N HCl (pH 1.2), and intermediate pH, acetate buffer (pH 4.5), followed by phosphate buffer, pH 6.8. The stability of the delayed release dosage forms was evaluated upon storage in accelerated conditions [40 degrees C/75% relative humidity] for 3 months.

RESULTS

All dosage forms demonstrated excellent enteric protection in the acid phase, followed by rapid release in their respective buffer media. Moreover, the delayed release dosage forms remained stable under accelerated stability conditions for 3 months.

CONCLUSIONS

Results showed that Acryl-EZE enteric coating systems provide excellent performance in both media (0.1N HCl and acetate buffer pH 4.5) for monolithic and multiparticulate dosage forms.

摘要

背景

质子泵抑制剂(PPIs)制成口服固体制剂具有挑战性,因为药物分子对酸不稳定。本研究旨在通过延迟释放薄膜包衣应用,评估三种 PPI 药物(即雷贝拉唑钠、兰索拉唑和埃索美拉唑镁)的不同制剂策略(整体和多颗粒)。

方法

雷贝拉唑钠的核心片剂采用有机湿法制粒法制备。多颗粒的兰索拉唑和埃索美拉唑镁通过糖球的药物分层,分别采用粉末分层和悬浮分层方法制备。对片剂和药物分层多颗粒进行密封包衣,然后使用 Acryl-EZE(R),水性丙烯酸肠溶系统进行延迟释放薄膜包衣应用。然后将多颗粒填充到胶囊中。对最终剂型进行物理性质评估,并在两种法定酸相(0.1N HCl,pH 1.2)和中间 pH 值(醋酸盐缓冲液,pH 4.5)以及磷酸盐缓冲液,pH 6.8 进行体外溶出度测试。在加速条件[40°C/75%相对湿度]下储存 3 个月,评估延迟释放剂型的稳定性。

结果

所有剂型在酸性相均表现出良好的肠保护作用,随后在各自的缓冲介质中快速释放。此外,延迟释放剂型在加速稳定性条件下 3 个月保持稳定。

结论

结果表明,Acryl-EZE 肠溶包衣系统在两种介质(0.1N HCl 和醋酸盐缓冲液 pH 4.5)中均为整体和多颗粒剂型提供了出色的性能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验